Literature DB >> 28286242

Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer.

Nir Peled1, Laila C Roisman2, Benjamin Miron3, Raphael Pfeffer4, Richard B Lanman5, Maya Ilouze2, Addie Dvir6, Lior Soussan-Gutman6, Fabrice Barlesi7, Gabi Tarcic3, Oded Edelheit3, David Gandara8, Yehiel Elkabetz9.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28286242     DOI： 10.1016/j.jtho.2017.02.023

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  14 in total

Review 1.  The next tier of EGFR resistance mutations in lung cancer.

Authors:  Hannah L Tumbrink; Alena Heimsoeth; Martin L Sos
Journal:  Oncogene       Date:  2020-10-15       Impact factor: 9.867

2.  EGFR mutation genotypes affect efficacy and resistance mechanisms of osimertinib in T790M-positive NSCLC patients.

Authors:  Qiufan Zheng; Yan Huang; Hongyun Zhao; Yunpeng Yang; Shaodong Hong; Xue Hou; Yuanyuan Zhao; Yuxiang Ma; Ting Zhou; Yaxiong Zhang; Wenfeng Fang; Li Zhang
Journal:  Transl Lung Cancer Res       Date:  2020-06

3.  Target-based genomic profiling of ctDNA from Chinese non-small cell lung cancer patients: a result of real-world data.

Authors:  Huijuan Chen; Aiqin Wang; Jing Wang; Zeming He; Yanqiu Mao; Liming Liu
Journal:  J Cancer Res Clin Oncol       Date:  2020-03-27       Impact factor: 4.553

4.  Development of a Fluorinated Analogue of Erlotinib for PET Imaging of EGFR Mutation-Positive NSCLC.

Authors:  Ofer Shamni; Hilbert Grievink; Batel Itamar; Eyal Mishani; Galith Abourbeh
Journal:  Mol Imaging Biol       Date:  2019-08       Impact factor: 3.488

5.  On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation.

Authors:  Benjamin P Brown; Yun-Kai Zhang; David Westover; Yingjun Yan; Huan Qiao; Vincent Huang; Zhenfang Du; Jarrod A Smith; Jeffrey S Ross; Vincent A Miller; Siraj Ali; Lyudmila Bazhenova; Alexa B Schrock; Jens Meiler; Christine M Lovly
Journal:  Clin Cancer Res       Date:  2019-02-22       Impact factor: 12.531

Review 6.  Preclinical Models for Acquired Resistance to Third-Generation EGFR Inhibitors in NSCLC: Functional Studies and Drug Combinations Used to Overcome Resistance.

Authors:  Emna Mahfoudhi; Charles Ricordel; Gwendoline Lecuyer; Cécile Mouric; Hervé Lena; Rémy Pedeux
Journal:  Front Oncol       Date:  2022-04-07       Impact factor: 5.738

7.  Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors.

Authors:  Jana Fassunke; Fabienne Müller; Marina Keul; Sebastian Michels; Marcel A Dammert; Anna Schmitt; Dennis Plenker; Jonas Lategahn; Carina Heydt; Johannes Brägelmann; Hannah L Tumbrink; Yannic Alber; Sebastian Klein; Alena Heimsoeth; Ilona Dahmen; Rieke N Fischer; Matthias Scheffler; Michaela A Ihle; Vanessa Priesner; Andreas H Scheel; Svenja Wagener; Anna Kron; Konrad Frank; Katia Garbert; Thorsten Persigehl; Michael Püsken; Stefan Haneder; Bernhard Schaaf; Ernst Rodermann; Walburga Engel-Riedel; Enriqueta Felip; Egbert F Smit; Sabine Merkelbach-Bruse; H Christian Reinhardt; Stefan M Kast; Jürgen Wolf; Daniel Rauh; Reinhard Büttner; Martin L Sos
Journal:  Nat Commun       Date:  2018-11-07       Impact factor: 14.919

Review 8.  Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer.

Authors:  Melina Marmarelis; Jeffrey C Thompson; Charu Aggarwal; Tracey L Evans; Erica Carpenter; Roger B Cohen; Corey J Langer; Joshua Bauml
Journal:  Ann Transl Med       Date:  2017-09

Review 9.  Impact of concurrent genomic alterations in epidermal growth factor receptor (EGFR)-mutated lung cancer.

Authors:  Beatrice Gini; Nicholas Thomas; Collin M Blakely
Journal:  J Thorac Dis       Date:  2020-05       Impact factor: 3.005

10.  Response to tyrosine kinase inhibitors in lung adenocarcinoma with the rare epidermal growth factor receptor mutation S768I and G724S: A case report and literature review.

Authors:  Cuicui Zhang; Li Lin; Ran Zuo; Yajie Wang; Peng Chen
Journal:  Thorac Cancer       Date:  2020-08-09       Impact factor: 3.500
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.